Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 10/2012

Inhalt (25 Artikel)

In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model

  • Original article

Alessa Pardo, Michael Stöcker, Florian Kampmeier, Georg Melmer, Rainer Fischer, Theo Thepen, Stefan Barth

TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines

  • Open Access
  • Original article

Kimberly R. Jordan, Jonathan D. Buhrman, Jonathan Sprague, Brandon L. Moore, Dexiang Gao, John W. Kappler, Jill E. Slansky

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation

  • Original article

Janina Rahlff, Maria Trusch, Friedrich Haag, Ulrike Bacher, Andrea Horst, Hartmut Schlüter, Mascha Binder

Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously

  • Original article

Jing Zhang, Jinpu Yu, Lili Yang, Hui Li, Feng Wei, Hua Zhao, Wenwen Yu, Xiubao Ren

Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer

  • Original article

Sumiya Ishigami, Takaaki Arigami, Yoshikazu Uenosono, Masataka Matsumoto, Hiroshi Okumura, Yasuto Uchikado, Yoshiaki Kita, Yuka Nishizono, Kosei Maemura, Yuko Kijima, Akihiro Nakajo, Tetsuhiro Owaki, Shinichi Ueno, Shuichi Hokita, Shoji Natsugoe

Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects

  • Original article

Alexander L. Rakhmilevich, Mark J. Baldeshwiler, Tyler J. Van De Voort, Mildred A. R. Felder, Richard K. Yang, Nicholas A. Kalogriopoulos, David S. Koslov, Nico Van Rooijen, Paul M. Sondel

Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK)

  • Original article

Jingling Liu, Wenna Chen, Jingjuan Meng, Changlong Lu, Enhua Wang, Fengping Shan

Inhibition of stromal CXCR4 impairs development of lung metastases

  • Open Access
  • Original article

Crescenzo D’Alterio, Antonio Barbieri, Luigi Portella, Giuseppe Palma, Marianeve Polimeno, Anna Riccio, Caterina Ieranò, Renato Franco, Giosuè Scognamiglio, Jane Bryce, Antonio Luciano, Domenica Rea, Claudio Arra, Stefania Scala

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

  • Original article

Timothy S. Fisher, Cris Kamperschroer, Theodore Oliphant, Victoria A. Love, Paul D. Lira, Regis Doyonnas, Simon Bergqvist, Sangita M. Baxi, Allison Rohner, Amy C. Shen, Chunli Huang, Sharon A. Sokolowski, Leslie L. Sharp

Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells

  • Original Article

Yan Zhou, Jing He, Lan-tu Gou, Bo Mu, Wei-chan Liao, Cong Ma, Ping Tang, Shi-jie Zhou, Yong-jun Zhou, Jin-liang Yang

Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity

  • Original article

Shuli Zhao, Huijuan Wang, Yunzhong Nie, Qiongyu Mi, Xingguo Chen, Yayi Hou

Macrophage polarization induced by neuropeptide methionine enkephalin (MENK) promotes tumoricidal responses

  • Original article

Wenna Chen, Jinling Liu, Jingjuan Meng, Changlong Lu, Ximing Li, Enhua Wang, Fengping Shan

Hodgkin’s lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses

  • Original article

Carolin Winkler, Daniel Sebastian Steingrube, Wolfgang Altermann, Gerald Schlaf, Daniela Max, Stefanie Kewitz, Alexander Emmer, Malte Kornhuber, Ursula Banning-Eichenseer, Martin Sebastian Staege

Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study

  • Open Access
  • Original article

Kazuro Iwai, Kenzo Soejima, Shoji Kudoh, Yoshimasa Umezato, Toru Kaneko, Kouji Yoshimori, Hitoshi Tokuda, Tetsuo Yamaguchi, Akira Mizoo, Yasuhiro Setoguchi, Takashi Kamigaki, Katsunada Fujimoto, Shigenori Goto

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

  • Original article

Eva Ellebaek, Lotte Engell-Noerregaard, Trine Zeeberg Iversen, Thomas Moerch Froesig, Shamaila Munir, Sine Reker Hadrup, Mads Hald Andersen, Inge Marie Svane

CA215 and GnRH receptor as targets for cancer therapy

  • Original article

Gregory Lee, Anthony P. Cheung, Bixia Ge, Mingang Zhu, Brett Giolma, Bo Li, Eric Wong, Yu Li, Yu Wang, Zinan Chen, Jiang Gu

Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma

  • Original article

Corey M. Munger, Ganapati V. Hegde, Dennis D. Weisenburger, Julie M. Vose, Shantaram S. Joshi

CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy

  • Original article

Sivan Sapoznik, Rona Ortenberg, Gilli Galore-Haskel, Stav Kozlovski, Daphna Levy, Camila Avivi, Iris Barshack, Cyrille J. Cohen, Michal J. Besser, Jacob Schachter, Gal Markel

Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

  • Original article

Hui Liu, Tiantuo Zhang, Jin Ye, Hongtao Li, Jing Huang, Xiaodong Li, Benquan Wu, Xubing Huang, Jinghui Hou

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model

  • Original article

Haihong Zhang, Yuqian Wang, Chenlu Liu, Lixing Zhang, Qiu Xia, Yong Zhang, Jiaxin Wu, Chunlai Jiang, Yan Chen, Yongge Wu, Xiao Zha, Xianghui Yu, Wei Kong

T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

  • Short communication

Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Daniela Brünnert, Frank Neumann, Lars Galonska, Uwe Reusch, Melvyn Little, Rainer Haas, Markus Uhrberg

Neu im Fachgebiet Onkologie

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Weniger aggressive Prostatakrebs-Therapie, gleiche Prognose

Erhalten ältere Prostatakrebs-Patienten vor Therapiebeginn ein geriatrisches Assessment, führt dies häufig zu einer Deeskalation der Behandlung – ohne dass ihre Prognose dadurch schlechter würde. Darauf deuten Erfahrungen aus Frankreich hin. 

Nach kardiovaskulärer Erkrankung steigt das Krebsrisiko

Wer an einer kardiovaskulären Erkrankung (CVD) leidet, hat offenbar ein erhöhtes Risiko, in der Folge auch noch eine Krebsdiagnose zu erhalten. Der Zusammenhang scheint für diverse CVD und Krebsentitäten zu gelten.

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.